1. Home
  2. OCS

as of 11-19-2026 3:59pm EST

$7.50
+$0.04
+0.60%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Oculis Holding AG is a biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The Company has locations in five countries: Switzerland, Iceland, France, U.S. and Hong Kong.

Founded: 2003 Country:
Switzerland
Switzerland
Employees: N/A City: N/A
Market Cap: 417.3M IPO Year: 2022
Target Price: $35.89 AVG Volume (30 days): 253.1K
Analyst Decision: Strong Buy Number of Analysts: 10
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $6.78 - $34.48 Next Earning Date: 11-03-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): -42.67% Revenue Growth (next year): 389.20%
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

Share on Social Networks: